S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
NYSE:ENFN

Enfusion (ENFN) Stock Price, News & Analysis

$8.67
-0.06 (-0.69%)
(As of 02/29/2024 ET)
Today's Range
$8.66
$8.91
50-Day Range
$7.78
$9.88
52-Week Range
$7.37
$12.00
Volume
676,312 shs
Average Volume
332,717 shs
Market Capitalization
$1.11 billion
P/E Ratio
108.39
Dividend Yield
N/A
Price Target
$9.40

Enfusion MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.80 Rating Score
Upside/​Downside
8.4% Upside
$9.40 Price Target
Short Interest
Bearish
4.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.53mentions of Enfusion in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$2.57 M Sold Last Quarter
Proj. Earnings Growth
88.89%
From $0.09 to $0.17 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Computer And Technology Sector

455th out of 601 stocks

Prepackaged Software Industry

165th out of 208 stocks


ENFN stock logo

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

ENFN Stock News Headlines

Goldman Sachs Downgrades Enfusion (ENFN)
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Enfusion to Host Investor Day on March 19, 2024
Enfusion downgraded to Underweight on client risks at JPMorgan
JP Morgan Downgrades Enfusion: Here's What You Need To Know
JPMorgan gets more bearish on Enfusion, downgrades shares
Enfusion: Product Is Sticky And Industry Is Huge
Enfusion (ENFN) Receives a Buy from William Blair
What You Can Learn From Enfusion, Inc.'s (NYSE:ENFN) P/S
Enfusion Names Neal Pawar COO - Quick Facts
Enfusion Announces Appointment of Chief Operating Officer
Enfusion Inc Class A ENFN
Enfusion: Still Bullish Considering Q3 EBITDA Beat
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/01/2024
Next Earnings (Confirmed)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,006
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.40
High Stock Price Target
$11.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+8.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-7,650,000.00
Pretax Margin
6.23%

Debt

Sales & Book Value

Annual Sales
$150.35 million
Book Value
$0.91 per share

Miscellaneous

Free Float
77,532,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
0.94
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 49)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 53)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 51)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Neal Pawar
    Chief Operating Officer
  • Ms. Valeria Gutowski (Age 42)
    Chief Accounting Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    General Counsel
  • Mr. Joseph Defeo
    Global Head of Managed Services Production
  • Mr. Jeff Young
    Head of Implementation














ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" ENFN shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price target for 2024?

5 brokerages have issued twelve-month price objectives for Enfusion's stock. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's stock price to reach $9.40 in the next year. This suggests a possible upside of 8.4% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2024?

Enfusion's stock was trading at $9.70 at the start of the year. Since then, ENFN shares have decreased by 10.6% and is now trading at $8.67.
View the best growth stocks for 2024 here
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our ENFN earnings forecast
.

How can I listen to Enfusion's earnings call?

Enfusion will be holding an earnings conference call on Tuesday, March 12th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

When did Enfusion IPO?

(ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Enfusion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (9.27%), Vanguard Group Inc. (2.83%), Northern Trust Corp (0.27%), Charles Schwab Investment Management Inc. (0.23%), Scalar Gauge Management LLC (0.16%) and Dimensional Fund Advisors LP (0.14%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe and Tarek Hammoud.
View institutional ownership trends
.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 3/1/2024 by MarketBeat.com Staff